Conclusion: Study data show that immunotherapy with Cvac is well tolerated. Immunological outcomes are consistent with the mechanism of action and the interim trends are encouraging for PFS."
10 months after the August 2012 encouraging interim trends they did a capital raising based on these conclusions and the above paragraph is part of the recently posted extract for the October 1 presentation.
Based on this alone the company has failed itself and all shareholders. I have always been critical of PRR's PR but this goes to the core of the company's competence and professionalism.
prr could be blockbuster from 1 october, page-17
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.010(3.08%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.0¢ | $584.2K | 1.787M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 311433 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 113721 | 6 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |